Stockscreener 앱 받기
3.86
0.26%
0.010
시간 외 거래:
3.86
전일 마감가:
$3.85
열려 있는:
$3.79
하루 거래량:
236.38K
Relative Volume:
1.26
시가총액:
$236.64M
수익:
$45.15M
순이익/손실:
$-39.23M
주가수익비율:
-2.1104
EPS:
-1.829
순현금흐름:
$-18.93M
1주 성능:
-5.85%
1개월 성능:
-16.27%
6개월 성능:
-21.22%
1년 성능:
-27.03%
1일 변동 폭
$3.70
$3.96
1주일 범위
$3.70
$4.38
52주 변동 폭
$3.42
$7.95
Trisalus Life Sciences Inc Stock (TLSI) Company Profile
명칭
Trisalus Life Sciences Inc
전화
415 336 8917
주소
6272 WEST 91ST AVENUE, WESTMINSTER
Compare TLSI vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TLSI
Trisalus Life Sciences Inc
|
3.86 | 236.03M | 45.15M | -39.23M | -18.93M | -1.829 |
|
ABT
Abbott Laboratories
|
107.19 | 188.52B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
339.76 | 132.34B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
86.87 | 111.97B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
69.89 | 105.77B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
82.46 | 47.98B | 6.07B | 1.06B | 1.34B | 1.8063 |
Trisalus Life Sciences Inc Stock (TLSI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-13 | 개시 | Lake Street | Buy |
| 2024-12-17 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-11-11 | 개시 | ROTH MKM | Buy |
| 2024-10-25 | 개시 | Northland Capital | Outperform |
| 2024-09-16 | 개시 | Oppenheimer | Outperform |
| 2024-05-30 | 개시 | Canaccord Genuity | Buy |
모두보기
Trisalus Life Sciences Inc 주식(TLSI)의 최신 뉴스
TriSalus Life Sciences launches proposed public stock offering - MSN
Should I invest in TriSalus Life Sciences Inc before earningsWall Street Watch & Technical Buy Zone Confirmations - baoquankhu1.vn
TriSalus publishes preclinical data on drug delivery technology By Investing.com - Investing.com Canada
TriSalus publishes preclinical data on drug delivery technology - Investing.com
Animal study from TriSalus pumps more immune drug into liver tumors in models - Stock Titan
Update Recap: What is the dividend yield of TriSalus Life Sciences Inc Equity WarrantRate Hike & Precise Entry and Exit Recommendations - baoquankhu1.vn
Published on: 2026-03-18 18:04:21 - baoquankhu1.vn
Analysis Recap: Is TriSalus Life Sciences Inc Equity Warrant benefiting from innovation trends2026 Key Lessons & Capital Efficiency Focused Ideas - baoquankhu1.vn
Canaccord lowers its price target on TriSalus Life Sciences, Inc. (TLSI) to $7 from $12 and maintains a buy rating - MSN
Canaccord Lowers its Price Target on TriSalus Life Sciences, Inc. (TLSI) to $7 from $12 and Maintains a Buy Rating - Insider Monkey
Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (TLSI), Cullinan Management (CGEM) and Pfizer (PFE) - The Globe and Mail
TriSalus Life Sciences Signals Confident Growth Path - TipRanks
11 Fastest Growing Penny Stocks to Buy Right Now - Insider Monkey
TLSIW Stock Price, News & Analysis - Stock Titan
Research Analysts Issue Forecasts for TLSI Q1 Earnings - MarketBeat
Canaccord Genuity Group Has Lowered Expectations for TriSalus Life Sciences (NASDAQ:TLSI) Stock Price - Defense World
TriSalus Life Sciences (NASDAQ:TLSI) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Analysts Offer Insights on Healthcare Companies: TriSalus Life Sciences (TLSI) and Shattuck Labs (STTK) - The Globe and Mail
Canaccord Genuity Group Issues Pessimistic Forecast for TriSalus Life Sciences (NASDAQ:TLSI) Stock Price - MarketBeat
Jones Trading reiterates Buy on TriSalus Life Sciences stock after earnings - Investing.com
TriSalus Life Sciences Q4 Earnings Call Highlights - Yahoo Finance
Boston Scientific to buy Penumbra in $14.5 billion deal - AOL.com
TriSalus Life Sciences reaffirms $60M–$62M revenue guidance for 2026 while expanding PEDD portfolio - MSN
Earnings call transcript: TriSalus Life Sciences sees 60% Q4 revenue rise - Investing.com
TriSalus (TLSI) Q4 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: TriSalus Life Sciences sees 60% Q4 revenue rise By Investing.com - Investing.com South Africa
TriSalus Life Sciences (NASDAQ:TLSI) Announces Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
TriSalus Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
TriSalus Life Sciences Reports Fourth Quarter and Year-End 2025 Results and Reaffirms 2026 Revenue Guidance - Bluefield Daily Telegraph
Earnings Summary: TriSalus Life Sciences Q4 - Benzinga
Cancer treatment tech firm TriSalus lifts 2025 sales 53%, aims $60-62M in 2026 - Stock Titan
TLSI: Strong revenue growth, expanded product suite, and robust 2026 outlook with $46M new capital - TradingView
TLSI SEC FilingsTriSalus Life Sciences Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Exploring TriSalus Life Sciences's Earnings Expectations - Benzinga
Northland Securities Forecasts TLSI FY2025 Earnings - MarketBeat
TriSalus Life Sciences Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
TLSI Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
TriSalus to Raise $40M from Stock Sale - National Today
TLSIW Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Retail Surge: What are TriSalus Life Sciences Inc Equity Warrants growth levers2025 Volatility Report & Growth Focused Stock Reports - baoquankhu1.vn
TriSalus Life Sciences (TLSI) to Release Earnings on Thursday - MarketBeat
TLSI PE Ratio & Valuation, Is TLSI Overvalued - Intellectia AI
TriSalus Life Sciences (NASDAQ: TLSI) raises ~$40M in 9.76M-share offering - Stock Titan
Cancer-focused medtech company TriSalus sets March 5 call on 2025 results - Stock Titan
TriSalus prices $40 mln public stock offering - MSN
TLSI Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Insider Buying: David Patience Acquires Shares of TriSalus Life Sciences Inc (TLSI) - GuruFocus
TLSI | TriSalus Life Sciences, Inc. Insider Trading - Quiver Quantitative
TLSI | TriSalus Life Sciences, Inc. FinancialsIncome Statement - Quiver Quantitative
TriSalus Life Sciences (TLSI) CFO adds 3,657 shares in open-market buy - Stock Titan
TriSalus director Gary Gordon buys 9,756 shares (TLSI) in open market - Stock Titan
Trisalus Life Sciences Inc (TLSI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.85%
1.86%
자본화:
|
볼륨(24시간):